<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33290920</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5883</ISSN><JournalIssue CitedMedium="Internet"><Volume>420</Volume><PubDate><Year>2021</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of the neurological sciences</Title><ISOAbbreviation>J Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Hypermetabolism is a reality in amyotrophic lateral sclerosis compared to healthy subjects.</ArticleTitle><Pagination><StartPage>117257</StartPage><MedlinePgn>117257</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jns.2020.117257</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-510X(20)30593-1</ELocationID><Abstract><AbstractText Label="RATIONALE">Hypermetabolism (HM) in Amyotrophic lateral sclerosis (ALS) is the reflection of a high energy metabolic level, but this alteration seems controversial. The main objective of the study was to confirm the existence of HM during ALS compared to healthy subjects.</AbstractText><AbstractText Label="METHODS">A cohort of ALS patients was compared to a control group without metabolic disorder. The assessment included anthropometric criteria measurements, body composition by bioelectric impedance analysis and resting energy expenditure (REE) by indirect calorimetry. HM was defined as a variation &gt; +10% between measured and calculated REE. Statistical analysis used Mann-Withney and Chi2 tests. Multivariate analysis included logistic regression.</AbstractText><AbstractText Label="RESULTS">287 patients and 75 controls were included. The metabolic level was higher in ALS patients (1500&#xa0;kcal/24&#xa0;h [1290-1693] vs. 1230&#xa0;kcal/24&#xa0;h [1000-1455], p&#xa0;&lt;&#xa0;0.0001) as well as the REE/fat free mass ratio (33.5&#xa0;kcal/kg/24&#xa0;h [30.4-37.8] vs. 28.3&#xa0;kcal/kg/24&#xa0;h [26.1-33.6], p&#xa0;&lt;&#xa0;0.0001). 55.0% of ALS patients had HM vs. 13.3% of controls (p&#xa0;&lt;&#xa0;0.0001). HM was strongly and positively associated with ALS (OR&#xa0;=&#xa0;9.50 [4.49-20.10], p&#xa0;&lt;&#xa0;0.0001).</AbstractText><AbstractText Label="CONCLUSIONS">HM in ALS is a reality, which affects more than half of the patients and is associated with ALS. This work confirms a very frequent metabolic deterioration during ALS. The identification of HM can allow a better adaptation of the patients' nutritional intake.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fayemendy</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Nutrition Unit, University Hospital of Limoges, Limoges, France; INSERM UMR 1094, Tropical Neuroepidemiology, Limoges, France. Electronic address: philippe.fayemendy@chu-limoges.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marin</LastName><ForeName>Benoit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>INSERM UMR 1094, Tropical Neuroepidemiology, Limoges, France; Center for Epidemiology, Biostatistics and Methodology of Research, University Hospital of Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labrunie</LastName><ForeName>Ana&#xef;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Epidemiology, Biostatistics and Methodology of Research, University Hospital of Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boirie</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>University Clermont Auvergne, INRA, UNH, Human Nutrition Unit, CRNH Auvergne, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walrand</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Clermont Auvergne, INRA, UNH, Human Nutrition Unit, CRNH Auvergne, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Achamrah</LastName><ForeName>Najate</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>INSERM UMR 1073, Normandie University, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Co&#xeb;ffier</LastName><ForeName>Mo&#xef;se</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM UMR 1073, Normandie University, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preux</LastName><ForeName>Pierre-Marie</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>INSERM UMR 1094, Tropical Neuroepidemiology, Limoges, France; Center for Epidemiology, Biostatistics and Methodology of Research, University Hospital of Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lautrette</LastName><ForeName>G&#xe9;raldine</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>ALS center, University Hospital of Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desport</LastName><ForeName>Jean-Claude</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Nutrition Unit, University Hospital of Limoges, Limoges, France; INSERM UMR 1094, Tropical Neuroepidemiology, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>INSERM UMR 1094, Tropical Neuroepidemiology, Limoges, France; ALS center, University Hospital of Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xe9;sus</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Nutrition Unit, University Hospital of Limoges, Limoges, France; INSERM UMR 1094, Tropical Neuroepidemiology, Limoges, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurol Sci</MedlineTA><NlmUniqueID>0375403</NlmUniqueID><ISSNLinking>0022-510X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001823" MajorTopicYN="N">Body Composition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002153" MajorTopicYN="N">Calorimetry, Indirect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Hypermetabolism</Keyword><Keyword MajorTopicYN="N">Resting energy expenditure</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>8</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33290920</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2020.117257</ArticleId><ArticleId IdType="pii">S0022-510X(20)30593-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>